Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE) a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), announced that the manuscript reporting the results of its phase III clinical trials of Zertane? for the treatment of the sexual dysfunction, premature ejaculation (PE), was accepted for publication in European Urology.

Read more at: http://pennygovernance.com/?p=16252